Verona Pharma Live Stream

Stream Discuss Polls Ratings Documents
Page

mol42 21 Nov 2017

Re: 3% Shareholders 091117 - rhodi Cheers Rhodimol

mol42 18 Nov 2017

Our Chairman fwiw article and apparently interview august 2017Leaders of disruptive innovation … what the leaders of the world’s most innovative companies actually doDr David Ebsworth is Chairman of Verona Pharma What are some of the unique challenges that leaders today face, and how should they address them?Resources are much more limited in my industry today than before. Regulations cover nearly everything and are changing constantly. Currency fluctuations have a massive impact on international businesses. These issues can be addressed by developing and following a long-term vision for the business and building the capability in the organization to understand the strategy, know each unit’s role in delivering this strategy, and setting up processes which enable action, with a clear understanding of each unit’s freedom to act.What are the three or four factors that are most critical to managing as a disruptive leader? How do you address each one?Having a clear vision of the future — Requires long term focus on the key factors to deliver. Challenging employees to be better than they think possible — Supporting rebels and people with the commitment to deliver. Forgiving mistakes and learning from them — Requires clear examples to be credible.In a recent insigniam executive sentiment study, 87% of executives said that innovation was critical to their continued competitive advantage, yet only 15% felt their organizations were well prepared to deliver the requisite innovation. In your opinion, why is there such a disparity?The speed of business is accelerating. Most organizations thrive on what they have done well in the past. This difference creates the issue. Few organizations support and reward innovation in a clear way.Can you quickly share some of your leadership challenges and how you addressed them?When I started in my new job, most people believed our most advanced development project was too late and too expensive to develop. I identified the key success factors with a cross-functional team approach and challenged them to deal with the issues. A year was cut from the time, and cost reduced significantly. As a result, a partnership deal was possible, which delivered significant short-term revenue. What have you done to create the conditions for sustained innovation in your enterprise?Not enough! More process is needed and the support of the true innovators should be clearer to the whole team.now presumably that deal which delivered short term revenue was turned down as we haven't had any such notification! however our Chairman at least continues to buy not only on open market but in our recent fund raising together with, i still believe to be SB (majority of same) though no evidence for said belief , in private placing separate from global offeringIn addition, the Chairman of Verona Pharma's board of directors, Dr. David Ebsworth, and an existing shareholder agreed to subscribe for 254,099 new ordinary shares at a price of £1.32 per ordinary share in a shareholder private placement separate from the Global Offering (the "Shareholder Private Placement", contingent on and concurrent with the Global Offering and generating additional gross proceeds of £335 thousand.[link] pdf 131117 presentation below [link] (down considerably over recent weeks but not out)

mol42 18 Nov 2017

Re: 3% Shareholders 091117 - rhodi Rhodi I note your comments re vs however no change in directors and mgt holding % at .5 since May 17 as per recent website update 9 nov and rns update 7 nov.And as we know no rns since. I don’t know why lse shows as nil and for how long it has but I would be very surprised if he had sold and company not informed or didn’t know and didn’t release an rns and whilst I’m comfortable he still holds i’m certainly hoping one isn’t released next week!I’m also though obviously very disappointed in sp since Nasdaq listing!I cannot find anything this afternoon to indicate otherwise re vs or any other pdmr selling.mol

millwallfan 09 Nov 2017

Re: 3% Shareholders 091117 As I have commented before I think it is a positive that no one fund hold sufficient to make a move to take control once there is the first whiff of major uplift through mass commercialisation. That won't stop a major pharma making a move. Let's hope Verona can match what gwpharmaceuiticals achieved in the USA

mol42 09 Nov 2017

3% Shareholders 091117 The Company's issued share capital consists of 105,017,401 ordinary shares with a nominal value of 5 pence each ("Ordinary Shares", each share having equal voting rights. The Company does not hold any Ordinary shares in treasury and therefore the number of Ordinary Shares with voting rights is 105,017,401.In accordance with AIM Rule 26, in so far as the Company is aware, the percentage of the Company's issued share capital that is not in public hands is 67.5%. The percentage of the Company's issued share capital held by the Directors and management is 0.5%.A number of European and US healtchare specialist investment firms have invested in the Company. At 9 November 2017, the interests in excess of 3% of the Company’s issued share capital are as set out in the table.Novo 11.80Vivo Funds 11.37OrbiMed 9.53New Enterprise Associates 9.29Abingworth 6.87Venbio Partners 6.67Rothschild 5.49Foresite Capital Management 4.76Tekla 4.20Aisling 3.38Arthurian 3.24just like to keep an eye on thisbw allmol

mol42 09 Nov 2017

Re: Abingworth video now on websiteperhaps someone reads this bb - lol[link]

mol42 30 Oct 2017

Re: Short video words - most of which we knowRPL554 is a dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. This dual inhibition enables it to combine bronchodilator and anti-inflammatory properties in one compound, differentiating it from existing drug classes used to treat COPD, including corticosteroids, beta2-agonists and anti-muscarinics.RPL554 also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance, thereby potentially also making it an attractive therapy for the treatment of CF.The three key activities of RPL554 in respiratory diseasesrevious attempts to develop PDE4 inhibitors for COPD, asthma and other indications have been limited by side effects, particularly those centered on the gastrointestinal system, such as nausea, vomiting and weight loss. RPL554 is designed to maximize effectiveness and reduce adverse events by:• relying on a chemical structure that is distinct from other PDE4 inhibitors to avoid gastrointestinal and other side effects typically associated with PDE4 inhibition;• having high selectivity for PDE3 and PDE4 over other enzymes and receptors to minimize off-target effects;• enabling delivery directly to the lung by inhalation, thereby maximizing pulmonary exposure to RPL554 while minimizing systemic distribution and potential adverse events.acting as an inhaled, dual inhibitor of PDE3 and PDE4 and stimulating the CFTR, we believe that RPL554 has the potential to be a more effective and better tolerated treatment of COPD than existing standalone PDE4 inhibitors. We also believe these properties give RPL554 broad potential applicability in the treatment of other respiratory diseases, including CF.mol

mol42 30 Oct 2017

Short video now uploaded this afternoon[link] on websitemol

mol42 13 Oct 2017

Since ... i was referenced on another bb, of which i review now and again and not difficult to follow thread - as here - methinks a certain poster does protest too much! just my opinion - but whilst he has some valid points which i have also posted here - he seems to have overlooked or ignored or ......VS $300,000 investment in april 17this remains my biggest aim holding - for better or worse - but i will continue to holdjust my opinion - whose else! lol where are all those posters on here btw?hmm - jees - aim of coursebye allunless[link]

mol42 12 Oct 2017

Abingworth recent video here[link]

mol42 12 Oct 2017

Investor Presentation 091017 [link] whilst spend is increasing (including cost of directors - i know!) we ain't going bust anytime soon!so for me i'll continue to hold my (reduced on consolidation) nice number - though haven't addedand it has been a longer wait than most lth here are well aware of !!bw allmol

mol42 10 Oct 2017

Re: Nasdaq Closing Bell 9/10/17 [link]

mol42 10 Oct 2017

Re: Nasdaq Closing Bell 9/10/17 [link]

paul1945 08 Oct 2017

Re: 3% Shareholders thanks 4 info

millwallfan 08 Oct 2017

Re: 3% Shareholders Thanks Mol. I only have a small holding here but am heartened that so many major ii's believe in the potential and even better that the mix and percentages almost certainly removes the potential for a hostile takeover unless there was a significant premium to current price. I am about 40% under water at the moment so sit and wait for me !

Page